This implies that passive immunization with tau antibodies is a viable therapeutic goal and the CSF standard of p-tau262/356 or on the microtubule binding area (MTBD) can serve as a helpful biomarker of tau pathology to observe tau therapeutics in medical trials.Even with these promising developments, you can find difficulties to deal with. Longitu